First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 12 050 GBX -0.87%
Updated: May 6, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

101.1B
+5%
Assets
Growth Rates:
1 Year
+5%
3 Years
+52%
5 Years
+67%
7 Years
+62%
10 Years
+81%
62B
+5%
Liabilities
Growth Rates:
1 Year
+4%
3 Years
+21%
5 Years
+29%
7 Years
+30%
10 Years
+90%
39.1B
+5%
Equity
Growth Rates:
1 Year
+6%
3 Years
+151%
5 Years
+214%
7 Years
+164%
10 Years
+69%

Balance Sheet Decomposition
AstraZeneca PLC

101.1B
Assets
62B
Liabilities
101.1B
Assets
62B
Liabilities
Current Assets 25.1B
Cash & Short-Term Investments 6B
Receivables 13.6B
Other Current Assets 5.5B
Non-Current Assets 76.1B
Long-Term Investments 1.7B
PP&E 10.5B
Intangibles 58.1B
Other Non-Current Assets 5.7B
Current Liabilities 30.5B
Accounts Payable 22.4B
Short-Term Debt 515m
Other Current Liabilities 7.7B
Non-Current Liabilities 31.4B
Long-Term Debt 23.2B
Other Non-Current Liabilities 8.2B

Balance Sheet
AstraZeneca PLC

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
6 360
6 240
5 018
3 324
4 831
5 369
7 832
6 329
6 166
5 840
Cash
1 009
1 250
782
784
893
755
1 182
1 461
1 411
1 325
Cash Equivalents
5 351
4 990
4 236
2 540
3 938
4 614
6 650
4 868
4 755
4 515
Short-Term Investments
795
613
884
1 230
849
849
160
69
239
122
Total Receivables
6 163
5 591
4 001
4 275
4 345
5 181
5 651
8 795
9 923
11 935
Accounts Receivables
4 762
4 633
2 583
2 802
2 995
3 813
3 956
6 324
7 508
8 859
Other Receivables
1 401
958
1 418
1 473
1 350
1 368
1 695
2 471
2 415
3 076
Inventory
1 960
2 143
2 334
3 035
2 890
3 193
4 024
8 983
4 699
5 424
Other Current Assets
1 419
1 420
1 025
1 286
2 676
971
1 877
2 068
1 566
1 733
Total Current Assets
16 697
16 007
13 262
13 150
15 591
15 563
19 544
26 244
22 593
25 054
PP&E Net
6 010
6 413
6 848
7 615
7 421
8 335
8 917
10 171
9 449
10 502
PP&E Gross
6 010
6 413
6 848
7 615
7 421
8 335
8 917
10 171
9 449
10 502
Accumulated Depreciation
7 734
7 435
6 603
7 024
7 218
7 517
8 193
8 324
7 743
8 599
Intangible Assets
20 981
22 646
27 586
26 188
21 959
20 833
20 947
42 387
39 307
38 089
Goodwill
11 550
11 800
11 658
11 825
11 707
11 668
11 845
19 997
19 820
20 048
Note Receivable
1 112
907
901
847
515
348
325
504
592
529
Long-Term Investments
561
543
826
1 036
922
1 459
1 147
1 237
1 142
1 677
Other Long-Term Assets
1 684
1 740
1 445
2 693
2 536
3 171
4 004
4 823
3 580
5 220
Other Assets
11 550
11 800
11 658
11 825
11 707
11 668
11 845
19 997
19 820
20 048
Total Assets
58 595
N/A
60 056
+2%
62 526
+4%
63 354
+1%
60 651
-4%
61 377
+1%
66 729
+9%
105 363
+58%
96 483
-8%
101 119
+5%
Liabilities
Accounts Payable
3 492
3 469
2 990
3 611
1 720
1 774
2 350
2 824
2 550
3 267
Accrued Liabilities
3 432
3 190
3 095
3 794
5 148
5 085
4 994
8 079
8 303
8 861
Short-Term Debt
196
189
94
152
160
154
370
387
350
515
Current Portion of Long-Term Debt
2 250
727
2 213
2 095
1 594
1 856
2 016
1 506
5 192
4 885
Other Current Liabilities
7 960
7 294
6 864
6 731
7 670
9 248
10 577
9 798
9 898
13 014
Total Current Liabilities
17 330
14 869
15 256
16 383
16 292
18 117
20 307
22 594
26 293
30 542
Long-Term Debt
8 397
14 137
14 501
15 560
17 359
16 217
17 994
28 888
23 690
23 222
Deferred Income Tax
1 796
2 665
3 956
3 995
3 286
2 490
2 918
6 206
2 944
2 844
Minority Interest
19
19
1 815
1 682
1 576
1 469
16
19
21
23
Other Liabilities
11 426
9 876
12 144
10 774
9 670
9 957
9 872
8 388
6 498
5 345
Total Liabilities
38 968
N/A
41 566
+7%
47 672
+15%
48 394
+2%
48 183
0%
48 250
+0%
51 107
+6%
66 095
+29%
59 446
-10%
61 976
+4%
Equity
Common Stock
316
316
316
317
317
328
328
387
387
388
Retained Earnings
15 050
13 870
10 187
10 250
7 724
4 858
7 323
3 755
1 495
3 567
Additional Paid In Capital
4 261
4 304
4 351
4 393
4 427
7 941
7 971
35 126
35 155
35 188
Total Equity
19 627
N/A
18 490
-6%
14 854
-20%
14 960
+1%
12 468
-17%
13 127
+5%
15 622
+19%
39 268
+151%
37 037
-6%
39 143
+6%
Total Liabilities & Equity
58 595
N/A
60 056
+2%
62 526
+4%
63 354
+1%
60 651
-4%
61 377
+1%
66 729
+9%
105 363
+58%
96 483
-8%
101 119
+5%
Shares Outstanding
Common Shares Outstanding
1 263
1 264
1 265
1 266
1 267
1 312
1 313
1 549
1 550
1 550

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.